Vertex Pharmaceuticals
Cell and gene therapy / small-molecule therapeutics
VRTX · Nasdaq · United States
Share price · VRTX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when VRTX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 3 Nov 2026-4.0%
- 30 Oct 2026+3.5%
Nothing announced by VRTX that day or the session before.
- 22 Oct 2026+2.0%
Nothing announced by VRTX that day or the session before.
- 10 Aug 2026+5.6%
Nothing announced by VRTX that day or the session before.
- 8 Jul 2026-4.6%
- 2 Jul 2026+6.0%
- 10 Mar 2026+8.3%
Nothing announced by VRTX that day or the session before.
- 17 Feb 2026-2.9%
Nothing announced by VRTX that day or the session before.
- 13 Feb 2026+5.7%
- 3 Dec 2025+6.9%
Nothing announced by VRTX that day or the session before.
Share of unusual movement by asset
For each asset, the share of VRTX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(15 total)
| Target & Modality | |||
|---|---|---|---|
Elexacaftor / tezacaftor / ivacaftor(Trikafta) | Approved | CFTR · CFTRSmall molecule | Cystic Fibrosis |
| Approved | BCL11A erythroid enhancer (gene editing)Gene therapy / editing | Sickle Cell DiseaseBeta-Thalassemia Transfusion-Dependent Beta Thalassemia | |
Ivacaftor(Kalydeco) | Approved | CFTRSmall molecule | Cystic Fibrosis |
lumacaftor(Orkambi) | Approved | CFTRSmall molecule | Cystic Fibrosis |
Suzetrigine(Journavx) | Approved | Voltage-gated sodium channel NaV1.8Small molecule | Diabetic Peripheral Neuropathic PainAcute Pain |
Tezacaftor / ivacaftor(Symdeko) | Approved | CFTRSmall molecule | Cystic Fibrosis |
Vanzacaftor / tezacaftor / deutivacaftor(Alyftrek) | Approved | CFTR · CFTRSmall molecule | Cystic Fibrosis |
| Phase 3 | BAFF / APRILProtein / enzyme therapeutic | Myasthenia GravisIgA NephropathyPrimary Membranous Nephropathy | |
| Phase 3 | Pancreatic islet cells (VX-880 is a stem cell-derived therapy, not a small molecule drug) · Pancreatic islet cell replacementCell therapy | Type 1 Diabetes | |
| Phase 2/3 | APOL1 (Apolipoprotein L1)Small molecule | Chronic Kidney DiseaseAPOL1-Mediated Kidney Disease | |
| Phase 2 | Polycystin-1 (PKD1 variants)Small molecule | Autosomal Dominant Polycystic Kidney Disease | |
| Phase 2 | DMPK CUG-repeat RNARNA / oligonucleotide | Myotonic Dystrophy Type 1 | |
| Phase 2 | Voltage-gated sodium channel NaV1.8Small molecule | Diabetic Peripheral Neuropathic Pain | |
| Phase 1 | CFTRSmall molecule | Cystic Fibrosis | |
| Discontinued | Pancreatic islet cell replacementCell therapy | Indication not yet linked |
Discontinued programmes (1)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
(23 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (14)
January 2027 (1)
What to watch
February 2027 (1)
March 2027 (2)
April 2027 (2)
May 2027 (1)
What to watch
June 2027 (2)
What to watch
What to watch
July 2027 (1)
September 2027 (1)
What to watch
November 2027 (1)
What to watch
2028 (2)
January 2028 (1)
What to watch
2029 (5)
January 2029 (1)
March 2029 (1)
What to watch
June 2029 (1)
What to watch
July 2029 (1)
What to watch
December 2029 (1)
What to watch
2030 (1)
June 2030 (1)
What to watch
2039 (1)
September 2039 (1)
What to watch
Regulatory and conference events
(15)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
The 12 most recent of 14 past events are shown.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $3.4B | $1.3B | $5.0B+ $1.3B short-term inv. | —$643M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $3.3B | $994M | $6.1B+ $1.7B short-term inv. | —$1.1B operating cash flow | report ↗ |
| 2026-Q1 | $3.0B | $962M | $5.5B+ $1.8B short-term inv. | —$1.4B operating cash flow | report ↗ |
| 2025-Q3 | $3.1B | $978M | $4.9B+ $1.3B short-term inv. | —$1.2B operating cash flow | report ↗ |
| 2025-Q2 | $3.0B | $978M | $5.0B+ $1.4B short-term inv. | —$1.1B operating cash flow | report ↗ |
| 2025-Q1 | $2.8B | $980M | $4.7B+ $1.5B short-term inv. | —$819M operating cash flow | report ↗ |
| 2024-Q3 | $2.8B | $876M | $5.2B+ $1.3B short-term inv. | —$1.4B operating cash flow | report ↗ |
| 2024-Q2 | $2.6B | $967M | $4.6B+ $1.2B short-term inv. | $3.6B-$3.8B operating cash flow | report ↗ |
| 2024-Q1 | $2.7B | $789M | $9.2B+ $1.0B short-term inv. | —$1.3B operating cash flow | report ↗ |
| 2023-Q3 | $2.5B | $810M | $11.1B+ $818M short-term inv. | —$1.3B operating cash flow | report ↗ |
| 2023-Q2 | $2.5B | $786M | $10.2B+ $1.1B short-term inv. | —$1.1B operating cash flow | report ↗ |
| 2023-Q1 | $2.4B | $743M | $9.3B+ $1.1B short-term inv. | —$900M operating cash flow | report ↗ |
| 2022-Q3 | $2.3B | $645M | $9.2B+ $599M short-term inv. | —$956M operating cash flow | report ↗ |
| 2022-Q2 | $2.2B | $600M | $8.7B+ $551M short-term inv. | —$1.1B operating cash flow | report ↗ |
| 2022-Q1 | $2.1B | $601M | $7.6B+ $638M short-term inv. | —$956M operating cash flow | report ↗ |
| 2021-Q3 | $2.0B | $467M | $6.3B+ $685M short-term inv. | —$927M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $12.0B | $3.9B | $5.1B+ $1.5B short-term inv. | —$3.6B operating cash flow | report ↗ |
Vertex reported full-year 2025 revenue of $12,001.3M, up 8.9% YoY, with R&D spend of $3,909.5M, up 7.7% YoY. Cash and equivalents stood at $5,084.8M, and net income was $3,953.2M.
The company guided full-year 2026 total revenue to $12.95B-$13.1B, including $500M or more from non-CF products. Pipeline progress includes the ongoing rolling BLA for povetacicept in IgAN, with completion expected in H1 2026, and multiple mid- and late-stage programs advancing; CASGEVY generated $116M in 2025 revenue, and JOURNAVX saw more than 550,000 prescriptions filled since launch.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $11.0B | $3.6B | $4.6B+ $1.5B short-term inv. | $134M-$493M operating cash flow | report ↗ |
| 2023-FY | $9.9B | $3.2B | $10.4B+ $849M short-term inv. | —$3.5B operating cash flow | report ↗ |
| 2022-FY | $8.9B | $2.5B | $10.5B+ $275M short-term inv. | —$4.1B operating cash flow | report ↗ |
| 2021-FY | $7.6B | $1.9B | $6.8B+ $730M short-term inv. | —$2.6B operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 91 sales ($140.1M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-16 | Bhatia Sangeeta N. · director | Open-market sale | 271 | $547.86 | $148K | Form 4 |
| 2026-11-16 | Thornberry Nancy · director | Open-market sale | 1,000 | $547.86 | $548K | Form 4 |
| 2026-11-12 | WAGNER CHARLES F JR · EVP, CO & FO | Open-market sale | 15,286 | $547.87 | $8.4M | Form 4 |
| 2026-11-06 | Kewalramani Reshma · director, CEO & President | Open-market sale | 11,866 | $531.53 | $6.3M | Form 4 |
| 2026-10-20 | Brennan Daniel J. · director | Award / grant | 795 | $503.47 | $400K | Form 4 |
| 2026-10-15 | Garber Alan M · director | Award / grant (derivative) | 29.272 | $512.44 | $15K | Form 4 |
| 2026-10-15 | SACHS BRUCE I · director | Award / grant (derivative) | 92.694 | $512.44 | $48K | Form 4 |
| 2026-09-08 | van Grunsven Jasper · EVP, CP and NPPO | Award / grant | 8,682 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 1,663 reporting institutions held 232.0M shares ($101.2B, 91.5% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Capital World Investors | 25,368,124 | $11.3B |
| 2 | BlackRock, Inc. | 23,969,517 | $10.7B |
| 3 | Capital Research Global Investors | 21,125,964 | $9.4B |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 16,512,810 | $7.4B |
| 5 | STATE STREET CORP | 11,730,139 | $5.2B |
| 6 | JPMORGAN CHASE & CO | 7,033,156 | $3.1B |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 6,139,621 | $2.7B |
| 8 | VANGUARD PORTFOLIO MANAGEMENT LLC | 5,145,609 | $2.3B |
| 9 | Capital International Investors | 5,126,077 | $2.3B |
| 10 | LOOMIS SAYLES & CO L P | 4,003,821 | $1.8B |
| 11 | ALLIANCEBERNSTEIN L.P. | 3,910,786 | $1.8B |
| 12 | WELLINGTON MANAGEMENT GROUP LLP | 3,212,589 | $1.4B |
| 13 | MORGAN STANLEY | 3,188,881 | $1.4B |
| 14 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 3,057,396 | $1.4B |
| 15 | BANK OF AMERICA CORP /DE/ | 2,878,183 | $1.3B |